175 related articles for article (PubMed ID: 24365550)
1. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
Jo KW; Lee SD; Kim WS; Kim DS; Shim TS
Int J Tuberc Lung Dis; 2014 Jan; 18(1):39-43. PubMed ID: 24365550
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
Chien JY; Chien ST; Chiu WY; Yu CJ; Hsueh PR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4708-16. PubMed ID: 27216062
[TBL] [Abstract][Full Text] [Related]
3. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
4. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Jiang RH; Xu HB; Li L
Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
7. Changes in treatment outcomes of multidrug-resistant tuberculosis.
Kwak N; Kim HR; Yoo CG; Kim YW; Han SK; Yim JJ
Int J Tuberc Lung Dis; 2015 May; 19(5):525-30. PubMed ID: 25868019
[TBL] [Abstract][Full Text] [Related]
8. Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Chien JY; Chiu WY; Chien ST; Chiang CJ; Yu CJ; Hsueh PR
Antimicrob Agents Chemother; 2016 Apr; 60(4):2090-6. PubMed ID: 26787695
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Rustomjee R; Lienhardt C; Kanyok T; Davies GR; Levin J; Mthiyane T; Reddy C; Sturm AW; Sirgel FA; Allen J; Coleman DJ; Fourie B; Mitchison DA;
Int J Tuberc Lung Dis; 2008 Feb; 12(2):128-38. PubMed ID: 18230244
[TBL] [Abstract][Full Text] [Related]
10. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs.
Codecasa LR; Ferrara G; Ferrarese M; Morandi MA; Penati V; Lacchini C; Vaccarino P; Migliori GB
Respir Med; 2006 Sep; 100(9):1566-72. PubMed ID: 16469488
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis.
Jo KW; Ji W; Hong Y; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Feb; 107(2):292-7. PubMed ID: 23199704
[TBL] [Abstract][Full Text] [Related]
12. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones for the treatment of tuberculosis in children.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
[TBL] [Abstract][Full Text] [Related]
16. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Koh WJ; Lee SH; Kang YA; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Chan Kim K; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee YS; Heo EY; Lee J; Ki YW; Shim TS; Yim JJ
Am J Respir Crit Care Med; 2013 Oct; 188(7):858-64. PubMed ID: 23927582
[TBL] [Abstract][Full Text] [Related]
17. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
18. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin.
Pinon M; Scolfaro C; Bignamini E; Cordola G; Esposito I; Milano R; Mignone F; Bertaina C; Tovo PA
Pediatrics; 2010 Nov; 126(5):e1253-6. PubMed ID: 20974784
[TBL] [Abstract][Full Text] [Related]
19. Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran.
Tabarsi P; Nooraki A; Mirsaeidi M; Amiri M; Baghaei P; Farnia P; Kazempour M; Heidarnazhad H; Alipanah N; Mansouri D; Masjedi MR
Respirology; 2008 Jan; 13(1):108-11. PubMed ID: 18197919
[TBL] [Abstract][Full Text] [Related]
20. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis.
Lee J; Lim HJ; Cho YJ; Park YS; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1331-3. PubMed ID: 22283890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
